The vast majority of p53 mutants lose the wild-type function or exert a ‘dominant-negative’ effect on the wild-type allele products; these mutations impair the activation of p53 target genes involved in suppressing tumour growth (loss of function, LOF). The gene discussed is TP53; the disease is neoplasm.